News
Merck & Co., Inc. (NYSE:MRK) is one of the top cheap pharmaceutical stocks to buy now. Goldman Sachs analyst Asad Haider ...
WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...
Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...
The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...
Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...
The stock's rise snapped a four-day losing streak.
Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...
Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...
Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results